DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether β-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome. METHODS: This was a prospective, multinational pharmacokinetic point-prevalence study including 8 β-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f T>MIC) and 100% (100% f T>MIC) of the dosing interval. We used skewed logistic regression to describe the effect of antibiotic exposure on patient outcome. RESULTS: We included 384 patients (361 evaluable patients) across 68 hospitals. The median age was 61 (interquartile range [IQR], 48-73) years, the median Acute Physiology and Chronic Health Evaluation II score was 18 (IQR, 14-24), and 65% of patients were male. Of the 248 patients treated for infection, 16% did not achieve 50% f T>MIC and these patients were 32% less likely to have a positive clinical outcome (odds ratio [OR], 0.68; P = .009). Positive clinical outcome was associated with increasing 50% f T>MIC and 100% f T>MIC ratios (OR, 1.02 and 1.56, respectively; P < .03), with significant interaction with sickness severity status. CONCLUSIONS: Infected critically ill patients may have adverse outcomes as a result of inadeqaute antibiotic exposure; a paradigm change to more personalized antibiotic dosing may be necessary to improve outcomes for these most seriously ill patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some observational studies suggested that prompt initiation of appropriate empiric antifungal therapy may be associated with a reduction in mortality, however these studies do not prove a causal relationship between antifungal therapy and outcome, nor do they clarify the role of timing of treatment, and some other studies have failed to show this association (167,(171)(172)(173).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [171]
In the citing paper
“Antibiotics are subject to changes in PK/PD parameters in sepsis and septic shock where resultant concentrations may be too low risking clinical failure, or too high leading to toxicity (Table 3) [237–239].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [238]
Citations
Cites
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376 · cited 1×
“Various demographic and clinical data were collected including age, sex, height, weight, presence of renal replacement therapy, and measures of organ function and levels of patient sickness severity as described by the APACHE II (Acute Physiology and Chronic Health Evaluation II) score [15] on admission and SOFA (Sequ…”
MethodKumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Vincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · cited 1×
“From a pharmacokinetic/pharmacodynamic (PK/PD) perspective, preclinical studies have defined these antibiotics to be time dependent, that is, the time for which the free (unbound) antibiotic concentration is maintained above the minimum inhibitory concentration (MIC) is the determinate factor associated with bacterial…”
BackgroundAntimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930 · cited 1×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundHarbarth, S., Garbino, J., Pugin, J., Romand, J. A., Lew, D., & Pittet, D. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.07.005 · Cited by 637
McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464 · cited 2×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundResultSubtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients
Udy, A. A., Varghese, J. M., Altukroni, M., Briscoe, S., McWhinney, B. C., Ungerer, J. P., Lipman, J., & Roberts, J. A. (2012) · Chest · doi:10.1378/chest.11-1671 · Cited by 414 · cited 1×
“These patients may have augmented renal clearances needing either higher doses or more frequent dosing to overcome increased drug elimination [22, 23].”
BackgroundSelf-citationAntibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J., & Póvoa, P. (2011) · Critical Care · doi:10.1186/cc10441 · Cited by 408 · cited 2×
“It has been suggested that superior infection outcomes could be achieved in critically ill patients by optimization of the pharmacokinetic exposure of antibiotics [5, 6].”
Background
Cited by
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citationSurviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Self-citationKalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
“These benefits from PK/PD optimization have also been detected during the treatment of infections other than HAP/ VAP [249].”
Self-citationSurviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Self-citationAntimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Self-citationRoberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., Hope, W. W., Farkas, A., Neely, M. N., Schentag, J. J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70036-2 · Cited by 1,046
Self-citationSepsis: a roadmap for future research
Cohen, J., Vincent, J.-L., Adhikari, N. K. J., Machado, F. R., Angus, D. C., Calandra, T., Jaton, K., Giulieri, S., Delaloye, J., Opal, S., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70112-x · Cited by 992
How to manage Pseudomonas aeruginosa infections
Bassetti, M., Vena, A., Croxatto, A., Righi, E., & Guery, B. (2018) · Drugs in Context · doi:10.7573/dic.212527 · Cited by 746
“concentrations sufficiently greater than the MIC required to ensure a positive clinical outcome [107].”
BackgroundSelf-citationGuilhaumou, R., Benaboud, S., Bennis, Y., Dahyot-Fizelier, C., Dailly, E., Gandia, P., Goutelle, S., Lefeuvre, S., Mongardon, N., Roger, C., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2378-9 · Cited by 543
“Such an important variability of Vd and clearance has been reported for almost all beta-lactam antibiotics [12, 26].”
BackgroundInfluentialMechanisms of antimicrobial resistance in Gram-negative bacilli
Ruppé, É., Woerther, P.-L., & Barbier, F. (2015) · Annals of Intensive Care · doi:10.1186/s13613-015-0061-0 · Cited by 490
“In this population, the pharmacokinetic properties of beta-lactams are dramatically modified [60–62], a pivotal point that may lead to sub-optimal BLBLI dosing even for ESBL-PE strains with relatively low MICs.”
BackgroundBloodstream infections in critically ill patients: an expert statement
Timsit, J.-F., Ruppé, E., Barbier, F., Tabah, A., & Bassetti, M. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05950-6 · Cited by 448
Self-citationBlot, S. I., Pea, F., & Lipman, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.07.006 · Cited by 444
“concentrations of beta-lactams were evaluated with as main PK/PD target free concentrations above the MIC of the pathogen at both 50% and 100% of the dosing interval [97].”
MethodSelf-citationAntibiotic stewardship in the intensive care unit
Luyt, C.-E., Bréchot, N., Trouillet, J.-L., & Chastre, J. (2014) · Critical Care · doi:10.1186/s13054-014-0480-6 · Cited by 388
“Frequently, higher than usually recommended antibiotic doses or continuous or extended infusions (or a combination of these) are needed [5,70,71,73,79,83-85].”
BackgroundInfluentialRoberts, J. A., Abdul-Aziz, M.-H., Davis, J. S., Dulhunty, J. M., Cotta, M. O., Myburgh, J., Bellomo, R., & Lipman, J. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0024oc · Cited by 379
Self-citationAbdul-Aziz, M. H., Sulaiman, H., Mat-Nor, M.-B., Rai, V., Wong, K. K., Hasan, M. S., Abd Rahman, A. N., Jamal, J. A., Wallis, S. C., Lipman, J., et al. (2016) · Intensive Care Medicine · doi:10.1007/s00134-015-4188-0 · Cited by 308
“Although actual MIC values would have been preferable, we believe that our approach resembles the real-life clinical approach where the MIC of a pathogen is rarely available upon antibiotic commencement [40].”
BackgroundSelf-citationRationalizing antimicrobial therapy in the ICU: a narrative review
Timsit, J.-F., Bassetti, M., Cremer, O., Daikos, G., de Waele, J., Kallil, A., Kipnis, E., Kollef, M., Laupland, K., Paiva, J.-A., et al. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05520-5 · Cited by 266
Self-citationA Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis
Dulhunty, J. M., Roberts, J. A., Davis, J. S., Webb, S. A. R., Bellomo, R., Gomersall, C., Shirwadkar, C., Eastwood, G. M., Myburgh, J., Paterson, D. L., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201505-0857oc · Cited by 264
Self-citationAugmented Renal Clearance in Critically Ill Patients: A Systematic Review
Bilbao-Meseguer, I., Rodríguez-Gascón, A., Barrasa, H., Isla, A., & Solinís, M. Á. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0636-7 · Cited by 241
“Traditionally, an fT[MIC of between 40 and 70% (depending on the agent) of the dosing interval has been accepted as a PK/PD target, although it has also been suggested that greater drug exposure, up to four times the MIC for the entire dosing interval, could improve clinical outcomes in critically ill patients [3, 55].”
BackgroundKollef, M. H., Torres, A., Shorr, A. F., Martin-Loeches, I., & Micek, S. T. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000004783 · Cited by 217
Self-citationAbdul-Aziz, M., Lipman, J., Mouton, J., Hope, W., & Roberts, J. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1398490 · Cited by 188
Self-citationHuttner, A., Von Dach, E., Renzoni, A., Huttner, B. D., Affaticati, M., Pagani, L., Daali, Y., Pugin, J., Karmime, A., Fathi, M., et al. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.12.017 · Cited by 220
Antimicrobial resistance: more than 70 years of war between humans and bacteria
Nadeem, S. F., Gohar, U. F., Tahir, S. F., Mukhtar, H., Pornpukdeewattana, S., Nukthamna, P., Moula Ali, A. M., Bavisetty, S. C. B., & Massa, S. (2020) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2020.1813687 · Cited by 209
Wong, G., Brinkman, A., Benefield, R. J., Carlier, M., De Waele, J. J., El Helali, N., Frey, O., Harbarth, S., Huttner, A., McWhinney, B., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt523 · Cited by 215
Self-citationSartelli, M., Weber, D. G., Ruppé, E., Bassetti, M., Wright, B. J., Ansaloni, L., Catena, F., Coccolini, F., Abu-Zidan, F. M., Coimbra, R., et al. (2016) · World Journal of Emergency Surgery · doi:10.1186/s13017-016-0089-y · Cited by 197
Self-citationVeiga, R. P., & Paiva, J.-A. (2018) · Critical Care · doi:10.1186/s13054-018-2155-1 · Cited by 203
Abdul-Aziz, M. H., Lipman, J., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Dulhunty, J., Kaukonen, K.-M., Koulenti, D., Martin, C., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv288 · Cited by 168
Self-citationHagel, S., Bach, F., Brenner, T., Bracht, H., Brinkmann, A., Annecke, T., Hohn, A., Weigand, M., Michels, G., Kluge, S., et al. (2022) · Intensive Care Medicine · doi:10.1007/s00134-021-06609-6 · Cited by 182
Self-citationAbdul-Aziz, M. H., Hammond, N. E., Brett, S. J., Cotta, M. O., De Waele, J. J., Devaux, A., Di Tanna, G. L., Dulhunty, J. M., Elkady, H., Eriksson, L., et al. (2024) · JAMA · doi:10.1001/jama.2024.9803 · Cited by 180
Self-citationNecrotising soft-tissue infections
Hua, C., Urbina, T., Bosc, R., Parks, T., Sriskandan, S., de Prost, N., & Chosidow, O. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00583-7 · Cited by 165
Dulhunty, J. M., Brett, S. J., De Waele, J. J., Rajbhandari, D., Billot, L., Cotta, M. O., Davis, J. S., Finfer, S., Hammond, N. E., Knowles, S., et al. (2024) · JAMA · doi:10.1001/jama.2024.9779 · Cited by 171
Self-citationTabah, A., Bassetti, M., Kollef, M. H., Zahar, J.-R., Paiva, J.-A., Timsit, J.-F., Roberts, J. A., Schouten, J., Giamarellou, H., Rello, J., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-019-05866-w · Cited by 191
Self-citationDe Waele, J. J., Lipman, J., Akova, M., Bassetti, M., Dimopoulos, G., Kaukonen, M., Koulenti, D., Martin, C., Montravers, P., Rello, J., et al. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3403-8 · Cited by 178
Self-citationSumi, C. D., Heffernan, A. J., Lipman, J., Roberts, J. A., & Sime, F. B. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00791-z · Cited by 181
Self-citationPreventive and therapeutic strategies in critically ill patients with highly resistant bacteria
Bassetti, M., De Waele, J. J., Eggimann, P., Garnacho-Montero, J., Kahlmeter, G., Menichetti, F., Nicolau, D. P., Paiva, J. A., Tumbarello, M., Welte, T., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-3719-z · Cited by 181
Self-citationPharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing
Onufrak, N. J., Forrest, A., & Gonzalez, D. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.06.015 · Cited by 170
Cook, A. M., & Hatton, J. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2231 · Cited by 188
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Intensive Care Medicine · doi:10.1007/s00134-026-08361-1 · Cited by 141
Self-citationWong, G., Briscoe, S., McWhinney, B., Ally, M., Ungerer, J., Lipman, J., & Roberts, J. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky314 · Cited by 169
Self-citationMangalore, R. P., Ashok, A., Lee, S. J., Romero, L., Peel, T. N., Udy, A. A., & Peleg, A. Y. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac506 · Cited by 167
Timing of antibiotic therapy in the ICU
Kollef, M. H., Shorr, A. F., Bassetti, M., Timsit, J.-F., Micek, S. T., Michelson, A. P., & Garnacho-Montero, J. (2021) · Critical Care · doi:10.1186/s13054-021-03787-z · Cited by 161
“The DALI study, a prospective, multicenter study, was primarily conducted to describe the frequency with which PK/pharmacodynamic (PK/PD) end points for β-lactam antibiotics were achieved in critically ill patients [53].”
BackgroundSelf-citationRoberts, J. A., Joynt, G. M., Lee, A. S. Y., Choi, G. Y. S., Bellomo, R., Kanji, S., Mudaliar, Y., Peake, S., Stephens, D. P., Taccone, F. S., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa224 · Cited by 170
Self-citationHobbs, A. L. V., Shea, K. M., Roberts, K. M., & Daley, M. J. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1653 · Cited by 165
“009).(45) Although the trial was not specific to patients with ARC, it highlights the importance of pharmacodynamic target attainment and the correlation with outcomes in critically ill patients.”
BackgroundMethodKollef, M. H., Bassetti, M., François, B., Burnham, J. P., Dimοpoulos, G., Garnacho‐Montero, J., Lipman, J., Luyt, C. E., Nicolau, D. P., Postma, M. J., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4682-7 · Cited by 165
“The presence of young adults with augmented creatinine clearance enrolled in these studies combined with antibiotic under dosing, resulting in reduced antibiotic plasma concentrations, may partly explain these negative study results [44].”
ResultSelf-citationAssays for therapeutic drug monitoring of β-lactam antibiotics: A structured review
Carlier, M., Stove, V. V., Wallis, S. C., Waele, J. J. D., Verstraete, A., Lipman, J., & Roberts, J. A. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.06.016 · Cited by 152
Self-citationXiao, A. J., Miller, B. W., Huntington, J. A., & Nicolau, D. P. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.566 · Cited by 152
Sinnollareddy, M., Roberts, J. A., Lipman, J., Akova, M., Bassetti, M., Waele, J. J. D., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., et al. (2015) · Critical Care · doi:10.1186/s13054-015-0758-3 · Cited by 154
“Thus, doses established based on the experience from other patient cohorts may not always be optimal to treat patients in ICU, as evidenced for antibacterial agents [15].”
BackgroundSelf-citationRoberts, D. M., Liu, X., Roberts, J. A., Nair, P. V., Cole, L., Roberts, M. S., Lipman, J., Bellomo, R., & On behalf of the RENAL Replacement Therapy Study Investigators (2015) · Critical Care · doi:10.1186/s13054-015-0818-8 · Cited by 149
“outcomes, including treatment failure [4] or the escalation of antibiotic resistance [5].”
BackgroundSelf-citationUdy, A. A., Lipman, J., Jarrett, P., Klein, K., Wallis, S. C., Patel, K., Kirkpatrick, C. M. J., Krüger, P., Paterson, D. L., Roberts, M. S., et al. (2015) · Critical Care · doi:10.1186/s13054-015-0750-y · Cited by 158
“They lead to poorly predictable and often subtherapeutic plasma concentrations [5].”
BackgroundMethodSelf-citationOptimizing antimicrobial use: challenges, advances and opportunities
Rawson, T. M., Wilson, R. C., O’Hare, D., Herrero, P., Kambugu, A., Lamorde, M., Ellington, M. J., Georgiou, P., Cass, A. E. G., Hope, W. W., et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00578-9 · Cited by 157
Ewoldt, T. M. J., Abdulla, A., Rietdijk, W. J. R., Muller, A. E., de Winter, B. C. M., Hunfeld, N., Purmer, I. M., van Vliet, P., Wils, E., Haringman, J. J., et al. (2022) · Intensive Care Medicine · doi:10.1007/s00134-022-06921-9 · Cited by 151
Huttner, A., Harbarth, S., Hope, W. W., Lipman, J., & Roberts, J. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv201 · Cited by 184
Self-citationA guide to therapeutic drug monitoring of β‐lactam antibiotics
Fratoni, A. J., Nicolau, D. P., & Kuti, J. L. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2505 · Cited by 152
Abdulla, A., Dijkstra, A., Hunfeld, N., Endeman, H., Bahmany, S., Ewoldt, T. M. J., Muller, A. E., van Gelder, T., Gommers, D. A. M. P. J., & Koch, B. C. P. (2020) · Critical Care · doi:10.1186/s13054-020-03272-z · Cited by 151
“found that critically ill patients failing to attain even the most conservative beta-lactam exposure target of 50% ƒT >MIC were 32% less likely to have a positive clinical outcome (defined as completion of treatment course without change or addition of antibiotic therapy) [21].”
BackgroundManagement of post-neurosurgical meningitis: narrative review
Hussein, K., Bitterman, R., Shofty, B., Paul, M., & Neuberger, A. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.05.013 · Cited by 142
Carrié, C., Petit, L., d’Houdain, N., Sauvage, N., Cottenceau, V., Lafitte, M., Foumenteze, C., Hisz, Q., Menu, D., Legeron, R., et al. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.11.013 · Cited by 153
The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs
Tabah, A., Waele, J. J. D., Lipman, J., Zahar, J., Cotta, M. O., Barton, G., Timsit, J., & Roberts, J. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv165 · Cited by 138
Self-citationSime, F. B., Udy, A. A., & Roberts, J. A. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.06.002 · Cited by 137
Self-citationAdvances in antibiotic therapy in the critically ill
Vincent, J., Bassetti, M., François, B., Karam, G. H., Chastre, J. E., Torres, A., Roberts, J. A., Taccone, F. S., Rello, J., Calandra, T., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1285-6 · Cited by 151
“Of these patients, 32 % were less likely to have a positive clinical outcome [48].”
BackgroundSelf-citationPseudomonas aeruginosa ventilator-associated pneumonia management
Rello, J., Ramirez‐Estrada, S., & Borgatta, B. (2016) · Infection and Drug Resistance · doi:10.2147/idr.s50669 · Cited by 155
Self-citationS3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge
Deutsche Sepsis Gesellschaft e., V., Brunkhorst, F. M., Weigand, M. A., Pletz, M. W., Gastmeier, P., Lemmen, S., Meier‐Hellmann, A., Ragaller, M., Weyland, A., Marx, G., et al. (2020) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-020-00685-0 · Cited by 148
Therapeutic drug monitoring of anti-infective agents in critically ill patients
Jager, N. G. L., van Hest, R. M., Lipman, J., Taccone, F. S., & Roberts, J. A. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1172209 · Cited by 134
“Large interindividual differences in PK of critically ill patients have been reported for aminoglycosides [37–41], glycopeptides [42–46], β-lactams [47,48], fluoroquinolones [49– 52], colistin [53,54], linezolid [49,55–59], daptomycin [60], fluconazole [61,62], itraconazole [63], posaconazole [64], voriconazole [65–67…”
BackgroundInfluentialSelf-citationMuller, A. E., Huttner, B. D., & Huttner, A. (2018) · Drugs · doi:10.1007/s40265-018-0880-z · Cited by 138
“The increasing interest in beta-lactam TDM has enabled a fairly consistent demonstration of the miscalculation [8, 52, 53].”
BackgroundMethodRhodes, N. J., Liu, J., O’Donnell, J. N., Dulhunty, J. M., Abdul-Aziz, M. H., Berko, P. Y., Nadler, B., Lipman, J., & Roberts, J. A. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002836 · Cited by 129
Self-citationAntibiotic therapy as personalized medicine – general considerations and complicating factors
Moser, C. E., Lerche, C. J., Thomsen, K., Hartvig, T., Schierbeck, J., Jensen, P. Ø., Ciofu, O., & Høiby, N. (2019) · Apmis · doi:10.1111/apm.12951 · Cited by 130
“ciated with an improved outcome, especially if the concentration was >MIC in 100% of the dosing interval (37).”
BackgroundInfluentialβ-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case–control study
Donadello, K., Antonucci, E., Cristallini, S., Roberts, J. A., Beumier, M., Scolletta, S., Jacobs, F., Rondelet, B., Backer, D. D., Vincent, J., et al. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.11.005 · Cited by 124
Self-citationSurviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Critical Care Medicine · doi:10.1097/ccm.0000000000007075 · Cited by 117
Self-citationTiseo, G., Brigante, G., Giacobbe, D. R., Maraolo, A. E., Gona, F., Falcone, M., Giannella, M., Grossi, P., Pea, F., Rossolini, G. M., et al. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106611 · Cited by 122
Self-citationUdy, A. A., Dulhunty, J. M., Roberts, J. A., Davis, J. S., Webb, S. A. R., Bellomo, R., Gomersall, C. D., Shirwadkar, C., Eastwood, G. M., Myburgh, J., et al. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.12.022 · Cited by 123
Self-citationAn approach to antibiotic treatment in patients with sepsis
Martínez, M. L., Plata-Menchaca, E. P., Ruiz‐Rodríguez, J. C., & Ferrer, R. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.01.47 · Cited by 134
“The Defining Antibiotic Levels in Intensive care unit patients (DALI) study (136), a large multicenter prospective study conducted in 248 patients with severe infection treated with beta-lactam antibiotics, found that one-fifth of patients did not achieve the PK/PD targets, and 500-fold differences in antibiotic blood…”
BackgroundBloodstream infections in the Intensive Care Unit
Bassetti, M., Righi, E., & Carnelutti, A. (2016) · Virulence · doi:10.1080/21505594.2015.1134072 · Cited by 125
Self-citationSurviving Sepsis Guidelines: A Continuous Move Toward Better Care of Patients With Sepsis
Backer, D. D., & Dorman, T. (2017) · JAMA · doi:10.1001/jama.2017.0059 · Cited by 112
Wong, G. Y. M., Sime, F. B., Lipman, J., & Roberts, J. A. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-288 · Cited by 124
Self-citationDetermining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria
Tam, V. H., Chang, K., Zhou, J. M., Ledesma, K. R., Phe, K., Gao, S., Françoise Van Bambeke, A., Díaz, A. M. S., Zamorano, L., Oliver, A., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx001 · Cited by 108
Clinical Pharmacokinetics and Pharmacodynamics of Cefepime
Pais, G. M., Chang, J. H. T., Barreto, E. F., Stitt, G. A., Downes, K. J., Al‐Shaer, M. H., Lesnicki, E., Panchal, V., Bruzzone, M., Bumanglag, A. V., et al. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01137-y · Cited by 110
“The results of the DALI study helped to support the findings of previous small studies that suggested that higher drug exposures are associated with improved outcomes among the critically ill [100, 101, 104].”
MethodResultBlot, S. I., Koulenti, D., Akova, M., Bassetti, M., Waele, J. J. D., Dimοpoulos, G., Kaukonen, K., Martin, C., Montravers, P., Rello, J., et al. (2014) · Critical Care · doi:10.1186/cc13874 · Cited by 108
Self-citationKühn, D., Metz, C., Seiler, F., Wehrfritz, H., Roth, S., Alqudrah, M., Becker, A. P., Bracht, H., Wagenpfeil, S., Hoffmann, M., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03397-1 · Cited by 112
“Two randomized trials [8, 9] elucidated that continuous infusion of meropenem and piperacillin were more likely to reach serum concentration goals in critically ill patients than intermittent infusion, and showed that continuous application was associated with a better clinical outcome [25].”
BackgroundDelattre, I., Taccone, F., Jacobs, F., Hites, M., Dugernier, T., Spapen, H. D., Laterre, P., Wallemacq, P. E., Françoise Van Bambeke, A., & Tulkens, P. M. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1338139 · Cited by 112
Self-citationCusumano, J. A., Klinker, K. P., Huttner, A., Luther, M. K., Roberts, J. A., & LaPlante, K. L. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa128 · Cited by 113
Self-citationUlldemolins, M., Soy, D., Llauradó‐Serra, M., Vaquer, S., Castro, P., Rodríguez, A. H., Pontes, C., Calvo, G., Torres, A., & Martín‐Loeches, I. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00712-15 · Cited by 112
Self-citationPharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient
Shah, S., Barton, G., & Fischer, A. (2015) · Journal of the Intensive Care Society · doi:10.1177/1751143714564816 · Cited by 99
“A recent large study that measured beta-lactam concentrations in critically ill patients showed that many patients did not achieve PK/PD targets and therefore may be less likely to achieve a positive clinical outcome.(3) Sub-therapeutic dosing of antibiotics may lead to the development of antibiotic resistance and/ or…”
BackgroundOptimization of dosing regimens and dosing in special populations
Sime, F. B., Roberts, M. S., & Roberts, J. A. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.05.002 · Cited by 99
Self-citationSepsis in pregnancy and the puerperium
Burlinson, C. E. G., Sirounis, D., Walley, K. R., & Chau, A. M. T. (2018) · International Journal of Obstetric Anesthesia · doi:10.1016/j.ijoa.2018.04.010 · Cited by 103
Meropenem use and therapeutic drug monitoring in clinical practice: a literature review
Steffens, N. A., Zimmermann, E. S., Nichelle, S. M., & Brucker, N. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13369 · Cited by 98
Sime, F. B., Roberts, M. S., Tiong, I. S., Gardner, J. H., Lehman, S., Peake, S., Hahn, U., Warner, M. S., & Roberts, J. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv123 · Cited by 99
Self-citationRichter, D., Frey, O. R., Röhr, A. C., Roberts, J. A., Koeberer, A., Fuchs, T., Papadimas, N., Heinzel‐Gutenbrunner, M., Brenner, T., Lichtenstern, C., et al. (2019) · Infection · doi:10.1007/s15010-019-01352-z · Cited by 106
“Consistently, intermittent bolus applications (IB) of standard doses are recognized as a main contributor for target non-attainment and potentially unfavorable patient outcome [9, 10].”
BackgroundResultSelf-citationAbdulla, A., Ewoldt, T. M. J., Hunfeld, N., Muller, A. E., Rietdijk, W. J. R., Polinder, S., van Gelder, T., Endeman, H., & Koch, B. C. P. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-4781-x · Cited by 102
“Target attainment is reported only in 60% of beta-lactam use in the ICU [16].”
BackgroundDiagnostic and medical needs for therapeutic drug monitoring of antibiotics
Mabilat, C., Gros, M.-F., Nicolau, D. P., Mouton, J. W., Textoris, J., Roberts, J. A., Cotta, M. O., van Belkum, A., & Caniaux, I. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03769-8 · Cited by 100
Self-citationPharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of Mouse Versus Man
Berry, A. V., & Kuti, J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.833189 · Cited by 92
Gatti, M., Cojutti, P. G., Bartoletti, M., Tonetti, T., Bianchini, A., Ramirez, S., Pizzilli, G., Ambretti, S., Giannella, M., Mancini, R., et al. (2022) · Critical Care · doi:10.1186/s13054-022-04050-9 · Cited by 91
Treatment of bloodstream infections in ICUs
Timsit, J., Soubirou, J.-F., Voiriot, G., Chemam, S., Neuville, M., Mourvillier, B., Sonneville, R., Mariotte, É., Bouadma, L., & Wolff, M. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-489 · Cited by 105
“Table 3 Suggested intravenous of initial selected antibiotic doses in critically ill patients during the first 24 hours of treatment of bacteremia with severe sepsis in ICU (to be adapted in case of kidney injury and renal replacement therapy) (adapted from [61,63-66]”
BackgroundBassetti, M., Carnelutti, A., & Peghin, M. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1251840 · Cited by 93
Self-citationCock, P. A. J. G. D., Standing, J. F., Barker, C. I. S., Jaeger, A. D., Dhont, E., Carlier, M., Verstraete, A., Delanghe, J., Robays, H., & Paepe, P. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01368-15 · Cited by 100
Optimizing Antimicrobial Drug Dosing in Critically Ill Patients
Póvoa, P. M. S. R., Moniz, P., Gonçalves-Pereira, J., & Coelho, L. (2021) · Microorganisms · doi:10.3390/microorganisms9071401 · Cited by 91
“Of note, evaluation of the targets 50% and 100% free T > 4*MIC did not show any additional benefit [207].”
Backgroundβ-lactam Therapeutic Drug Management in the PICU*
Cies, J. J., Moore, W. S., Enache, A., & Chopra, A. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002817 · Cited by 95
Roberts, J. A., Taccone, F. S., & Lipman, J. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-4032-6 · Cited by 100
“This ‘‘one dose fits all’’ approach would appear to be problematic in critically ill patients, as the DALI Study [4], among others [10–13], have demonstrated clear concentration–effect relationships for antibiotics where achievement of PK/PD targets is associated with improved clinical cure and/or patient survival.”
BackgroundResultSelf-citationClassic reaction kinetics can explain complex patterns of antibiotic action
Wiesch, P. A. Z., Abel, S., Gkotzis, S., Ocampo, P., Engelstädter, J., Hinkley, T., Magnus, C., Waldor, M. K., Udekwu, K. I., & Cohen, T. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa8760 · Cited by 92
“Several recent clinical studies have been designed to address the impact of different antibiotic concentrations on patient outcome (9, 10).”
Pinder, N., Brenner, T., Swoboda, S., Weigand, M. A., & Hoppe‐Tichy, T. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.05.037 · Cited by 85
Lefeuvre, S., Bois-Maublanc, J., Hocqueloux, L., Bret, L., Francia, T., violante, C. E.-D., Billaud, E. M., Barbier, F., & Got, L. (2017) · Journal of Chromatography B · doi:10.1016/j.jchromb.2017.09.014 · Cited by 85
Barreto, E. F., Webb, A. J., Pais, G. M., Rule, A. D., Jannetto, P. J., & Scheetz, M. H. (2021) · Critical Care Explorations · doi:10.1097/cce.0000000000000446 · Cited by 86
Metadata
- Authors
- Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., Rello, J., Rhodes, A., Starr, T., Wallis, S. C., Lipman, J., Study, D., Roberts, J. A., Lipman, J., Starr, T., Wallis, S. C., Paul, S. K., Margarit Ribas, A., De Waele, J. J., De Crop, L., Spapen, H., Wauters, J., Dugernier, T., Jorens, P., Dapper, I., De Backer, D., Taccone, F. S., Rello, J., Ruano, L., Afonso, E., Alvarez-Lerma, F., Gracia-Arnillas, M. P., Fernandez, F., Feijoo, N., Bardolet, N., Rovira, A., Garro, P., Colon, D., Castillo, C., Fernado, J., Lopez, M. J., Fernandez, J. L., Arribas, A. M., Teja, J. L., Ots, E., Carlos Montejo, J., Catalan, M., Prieto, I., Gonzalo, G., Galvan, B., Blasco, M. A., Meyer, E., Del Nogal, F., Vidaur, L., Sebastian, R., Garde, P. M., Martin Velasco, M. D. M., Zaragoza Crespo, R., Esperatti, M., Torres, A., Montravers, P., Baldesi, O., Dupont, H., Mahjoub, Y., Lasocki, S., Constantin, J. M., Payen, J. F., Martin, C., Albanese, J., Malledant, Y., Pottecher, J., Lefrant, J.-Y., Jaber, S., Joannes-Boyau, O., Orban, C., Ostermann, M., McKenzie, C., Berry, W., Smith, J., Lei, K., Rubulotta, F., Gordon, A., Brett, S., Stotz, M., Templeton, M., Rhodes, A., Ebm, C., Moran, C., Kaukonen, K.-M., Pettila, V., Dimopoulos, G., Koulenti, D., Xristodoulou, A., Theodorou, V., Kouliatsis, G., Sertaridou, E., Anthopoulos, G., Choutas, G., Rantis, T., Karatzas, S., Balla, M., Papanikolaou, M., Myrianthefs, P., Gavala, A., Fildisis, G., Koutsoukou, A., Kyriakopoulou, M., Petrochilou, K., Kompoti, M., Michalia, M., Clouva-Molyvdas, F.-M., Gkiokas, G., Nikolakopoulos, F., Psychogiou, V., Malliotakis, P., Akoumianaki, E., Lilitsis, E., Koulouras, V., Nakos, G., Kalogirou, M., Komnos, A., Zafeiridis, T., Chaintoutis, C., Arvaniti, K., Matamis, D., Chaintoutis, C., Kydona, C., Gritsi-Gerogianni, N., Giasnetsova, T., Giannakou, M., Soultati, I., Chytas, I., Antoniadou, E., Antipa, E., Lathyris, D., Koukoubani, T., Paraforou, T., Spiropoulou, K., Bekos, V., Spring, A., Kalatzi, T., Nikolaou, H., Laskou, M., Strouvalis, I., Aloizos, S., Kapogiannis, S., Soldatou, O., Bassetti, M., Adembri, C., Villa, G., Giarratano, A., Maurizio Raineri, S., Cortegiani, A., Montalto, F., Strano, M. T., Ranieri, V. M., Sandroni, C., De Pascale, G., Molin, A., Pelosi, P., Montagnani, L., Urbino, R., Mastromauro, I., De Rosa, F. G., Ranieri, V. M., Cardoso, T., Afonso, S., Goncalves-Pereira, J., Baptista, J. P., Akova, M., & Ozveren, A.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- The University of Queensland (AU)
- Ghent University Hospital (BE)
- Centre Hospitalier Universitaire de Nîmes (FR)
- University General Hospital Attikon (GR)
- Sorbonne Paris Cité (FR)
- St George's, University of London (GB)
- University of Palermo (IT)
- University of Genoa (IT)
- Hacettepe University (TR)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-14
- Volume
- 58
- Issue
- 8
- Pages
- 1072-1083
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2101416655
- Cited by
- 1,090
- References
- 31
- Citations by year
- 2026: 75 · 2025: 98 · 2024: 83 · 2023: 125 · 2022: 115 · 2021: 125 · 2020: 86 · 2019: 84 · 2018: 69 · 2017: 71 · 2016: 66 · 2015: 57 · 2014: 34
- FWCI
- 55.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- HAL (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NIHR/CS/009/007)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- beta-lactam antibiotics, antibiotic dosing, critically ill patients, intensive care unit, pharmacokinetics, pharmacodynamics, free drug concentration, time above MIC, patient outcomes
- MeSH terms
- Aged, Anti-Bacterial Agents, Bacterial Infections, Blood Chemical Analysis, Female, Humans, Intensive Care Units, International Cooperation, Male, Microbial Sensitivity Tests, Middle Aged, Prospective Studies, Models, Statistical, Critical Illness, Treatment Outcome, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.